Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Alcon Inc.: PharmaVitae Profile

IntroductionThis analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.ScopeHighlightsReasons to PurchaseBenchmark Alcon's performance against key rivals in the prescription pharmaceutical sectorSee how new launches have driven the company's impressive growth throughout the historic periodAssess how Alcon's tight therapeutic performance will affect its performance out to 2014 and the returns on Novartis' investment

Related Books

Free with a 30 day trial from Scribd

See all
  • Be the first to comment

  • Be the first to like this

Alcon Inc.: PharmaVitae Profile

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Alcon Inc.: PharmaVitae ProfilePublished on July 2010 Report SummaryIntroductionThis analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profileencompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year salesforecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitativeinformation.ScopeHighlightsReasons to PurchaseBenchmark Alcons performance against key rivals in the prescription pharmaceutical sectorSee how new launches have driven thecompanys impressive growth throughout the historic periodAssess how Alcons tight therapeutic performance will affect itsperformance out to 2014 and the returns on Novartis investment Table of ContentABOUT DATAMONITOR HEALTHCARE 2About the PharmaVitae team 2Chapter 1 About this profile 3PharmaVitae Explorer database 3Chapter structure 3Executive summary 3Quarterly news update 3Company introduction 3Company sales 4Company financials 4Key products and competitors 4Data sourcing 4Sales data 4Analyst consensus 4Chapter 2 Executive summary 5Alcon Inc.: PharmaVitae Profile Page 1/7
  2. 2. Find Industry reports, Company profilesReportLinker and Market StatisticsKey findings 5Prescription pharmaceutical sales and growth rate performance, 2002-14 6Financial performance, 2002-14 7Alcon: PharmaVitae forecasts at a glance 8Strategic insight 9Global leader in ophthalmology 9Broad coverage of attractive markets 9Margin expansion to maximize operating profit 9Ophthalmology focus may restrict opportunity 11Challenges faced in ophthalmic markets 11Limited availability of externally discovered products 11Potential consolidation with Novartis would allow further synergies 13Two-step agreement to sell Nestlés holding 13Complementary fit with Novartiss ophthalmics business 14Majority stake will not alone allow integration of the two businesses 15SWOT analysis 16Table of Contents 17Table of figures 19Chapter 3 Quarterly news update 20Key findings 20Product developments 21Deals and alliances 22Product deals 22Technology deals 22M&A activity 23Company announcements 23Future product milestones 24Chapter 4 Company introduction 25Key findings 25Background 26Key corporate developments 26M&A history 27Current corporate structure 29Chapter 5 Company sales 30Key findings 30Prescription pharmaceutical sales and growth rate analysis, 2002-14 31Product analysis 33Product analysis, 2002-08 34Product analysis, 2008-14 37Therapy area analysis 41Geographic analysis 47Launch/core/expiry analysis 50Explanation of launch/core/expiry analysis 50Launch analysis, 2008-14 51Core analysis, 2008-14 53Expiry analysis, 2008-14 55Generics analysis, 2008-14 57Launch/core/expiry configuration, 2008-14 58Molecule type analysis 59Externalization analysis 61Alcon Inc.: PharmaVitae Profile Page 2/7
  3. 3. Find Industry reports, Company profilesReportLinker and Market StatisticsChapter 6 Company financials 63Key findings 63Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 64Operating costs and profit analysis 66Operating costs and profit analysis, 2002-08 67Operating cost ratio and profit margin analysis, 2002-08 68Operating cost ratio and profit margin analysis, 2008-14 69Operating costs and profit analysis, 2008-14 71Chapter 7 Key products and competitors 73Key findings 73Overview 74Other 75Travatan franchise 75Overview 75Sales forecast 76Market uptake against gold standard, Xalatan 76Increasing competition from indirect generics 77Travatan Z helps to differentiate Alcons offering 77Threat of earlier than forecast direct generics 78Azopt 79Overview 79Sales forecast 80Competition with the Trusopt franchise in the carbonic anhydrase inhibitor class 80Generic carbonic anhydrase inhibitors became available from October 2008 80Azarga strengthens ex-US sales 81Patanol franchise 82Overview 82Sales forecast 83Maximization of deal with Kyowa Hakko Kirin 83Generic copies of key competitor from 2009 84Infectious diseases 85Vigamox 85Overview 85Sales forecast 86Fourth-generation anti-infective 86Delays reduce further opportunity for switching 86Ciprodex 88Overview 88Sales forecast 89Generic copies forecast to launch in the US from 2010 89MoxiDex Otic will launch too late to allow direct switching 89Respiratory 90Patanase 90Overview 90Sales forecast 91Initial market uptake will clarify potential 91Generic copies of Astelin threaten sales from 2010 91Chapter 8 Appendix 93R&D pipeline 93Therapy area by company reporting line 94Alcon Inc.: PharmaVitae Profile Page 3/7
  4. 4. Find Industry reports, Company profilesReportLinker and Market StatisticsReferences 98Abbreviations 98Exchange rates 100About Datamonitor 101About Datamonitor Healthcare 101Datamonitor consulting 101Disclaimer 103List of TablesTable 1: Alcon - PharmaVitae forecasts at a glance 8Table 2: Alcon key product developments, Q1-Q3 2009 21Table 3: Alcon product deals and alliances, Q1-Q3 2009 22Table 4: Alcon technology deals and alliances, Q1-Q3 2009 22Table 5: Alcon M&A activity, Q1-Q3 2009 23Table 6: Alcon company announcements, Q1-Q3 2009 23Table 7: Alcon future product milestones, 2009-11 24Table 8: Alcon product portfolio overview ($m), 2002-08 34Table 9: Alcon product portfolio overview ($m), 2008-14 37Table 10: Alcon prescription pharmaceutical sales by therapy area ($m), 2008-14 46Table 11: Alcon prescription pharmaceutical sales by geographic region ($m), 2008-14 49Table 12: Alcon launch portfolio overview ($m), 2008-14 51Table 13: Alcon core portfolio overview ($m), 2008-14 53Table 14: Alcon expiry portfolio overview ($m), 2008-14 55Table 15: Alcon generics portfolio overview ($m), 2008-14 57Table 16: Alcon prescription pharmaceutical sales by molecule type ($m), 2008-14 60Table 17: Alcon prescription pharmaceutical sales by source ($m), 2008-14 62Table 18: Total Alcon sales by business unit ($m), 2002-08 64Table 19: Alcon operating revenue/cost analysis ($m), 2002-08 67Table 20: Alcon operating cost ratio analysis (% of total revenues), 2002-08 68Table 21: Alcon operating cost ratio analysis (% of total revenues), 2008-14 69Table 22: Alcon operating revenue/cost analysis ($m), 2008-14 71Table 23: Key products overview 74Table 24: Travatan: overview 75Table 25: Travatan franchise: sales forecast ($m), 2008-14 76Table 26: DuoTrav: sales forecast ($m), 2008-14 76Table 27: Azopt: overview 79Table 28: Azopt: sales forecast ($m), 2008-14 80Table 29: Patanol: overview 82Table 30: Patanol franchise: sales forecast ($m), 2008-14 83Table 31: Vigamox: overview 85Table 32: Vigamox: sales forecast ($m), 2008-14 86Table 33: Ciprodex: overview 88Table 34: Ciprodex: sales forecast ($m), 2008-14 89Table 35: Patanase: overview 90Table 36: Patanase: sales forecast ($m), 2008-14 91Table 37: Alcons R&D pipeline (Phase I-registration) 93Table 38: Alcon product portfolio overview ($m), 2002-08 94Table 39: Alcon product portfolio overview ($m), 2008-14 96Table 40: Exchange rates, 2009 100Alcon Inc.: PharmaVitae Profile Page 4/7
  5. 5. Find Industry reports, Company profilesReportLinker and Market StatisticsList of FiguresFigure 1: The PharmaVitae Explorer 3Figure 2: Alcon prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6Figure 3: Alcons financial performance ($m), 2002-14 7Figure 4: Alcon total revenue and operating profit breakdown, 2002-14 10Figure 5: Alcon share price and timeframe of put/call options on Nestlés remaining 52% stake, 2002-11 13Figure 6: Synergies between Alcon and Novartis 14Figure 7: Alcon SWOT analysis 16Figure 8: Recent and major M&A/divestment activity, Alcon 27Figure 9: Current corporate structure 29Figure 10: Alcon prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 31Figure 11: Key product sales ($m), 2002-14 33Figure 12: Alcon key sales growth drivers and resistors ($m), 2002-08 35Figure 13: Alcon key sales growth drivers and resistors ($m), 2008-14 38Figure 14: Alcon prescription pharmaceutical sales by therapy area ($m), 2002-14 41Figure 15: Alcon prescription pharmaceutical sales by product category ($m), 2002-14 42Figure 16: Alcon prescription pharmaceutical sales by geographic region ($m), 2002-14 47Figure 17: Alcon launch/core/expiry configuration ($m), 2008-14 58Figure 18: Alcon prescription pharmaceutical sales by molecule type ($m), 2002-14 59Figure 19: Alcon prescription pharmaceutical sales by source ($m), 2002-14 61Figure 20: Alcon operating revenue/cost analysis ($m), 2002-14 66Alcon Inc.: PharmaVitae Profile Page 5/7
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Alcon Inc.: PharmaVitae Profile Product Formats Please select the product formats and the quantity you require. Digital Copy--USD 5 700.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Alcon Inc.: PharmaVitae Profile Page 6/7
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Alcon Inc.: PharmaVitae Profile Page 7/7

    Be the first to comment

    Login to see the comments

IntroductionThis analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.ScopeHighlightsReasons to PurchaseBenchmark Alcon's performance against key rivals in the prescription pharmaceutical sectorSee how new launches have driven the company's impressive growth throughout the historic periodAssess how Alcon's tight therapeutic performance will affect its performance out to 2014 and the returns on Novartis' investment

Views

Total views

290

On Slideshare

0

From embeds

0

Number of embeds

1

Actions

Downloads

0

Shares

0

Comments

0

Likes

0

×